Your browser doesn't support javascript.
loading
Impact of molecular residual disease post allografting in myelofibrosis patients.
Wolschke, C; Badbaran, A; Zabelina, T; Christopeit, M; Ayuk, F; Triviai, I; Zander, A; Alchalby, H; Bacher, U; Fehse, B; Kröger, N.
Afiliación
  • Wolschke C; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Badbaran A; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Zabelina T; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Christopeit M; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Ayuk F; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Triviai I; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Zander A; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Alchalby H; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Bacher U; Department of Hematology and Oncology, University Hospital Göttingen, Göttingen, Germany.
  • Fehse B; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Kröger N; Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Bone Marrow Transplant ; 52(11): 1526-1529, 2017 Nov.
Article en En | MEDLINE | ID: mdl-28714945
ABSTRACT
We screened 136 patients with myelofibrosis and a median age of 58 years who underwent allogeneic stem cell transplantation (AHSCT) for molecular residual disease for JAKV617F (n=101), thrombopoietin receptor gene (MPL) (n=4) or calreticulin (CALR) (n=31) mutation in peripheral blood on day +100 and +180 after AHSCT. After a median follow-up of 78 months, the 5-year estimated overall survival was 60% (95% confidence interval (CI) 50-70%) and the cumulative incidence of relapse at 5 years was 26% (95% CI 18-34%) for the entire study population. The percentage of molecular clearance on day 100 was higher in CALR-mutated patients (92%) in comparison with MPL- (75%) and JAKV617F-mutated patients (67%). Patients with detectable mutation at day +100 or at day +180 had a significant higher risk of clinical relapse at 5 years than molecular-negative patients (62% vs 10%, P<0.001) and 70% vs 10%, P<0.001, respectively) irrespectively of the underlying mutation. In a multivariate analysis, high-risk diseases status (hazard ratio (HR) 2.5; 95% CI 1.18-5.25, P=0.016) and detectable MRD at day 180 (HR 8.36, 95% CI 2.76-25.30, P<0.001) were significant factors for a higher risk of relapse.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasia Residual / Calreticulina / Janus Quinasa 2 / Receptores de Trombopoyetina / Mielofibrosis Primaria / Patología Molecular Tipo de estudio: Diagnostic_studies Límite: Humans / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasia Residual / Calreticulina / Janus Quinasa 2 / Receptores de Trombopoyetina / Mielofibrosis Primaria / Patología Molecular Tipo de estudio: Diagnostic_studies Límite: Humans / Middle aged Idioma: En Revista: Bone Marrow Transplant Asunto de la revista: TRANSPLANTE Año: 2017 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: ENGLAND / ESCOCIA / GB / GREAT BRITAIN / INGLATERRA / REINO UNIDO / SCOTLAND / UK / UNITED KINGDOM